- Home
- CRMD vs LENZ Comparison
CRMD vs LENZ Comparison
Compare CRMD & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRMD
- LENZ
- Stock Information
- Founded
- CRMD 2006
- LENZ 2019
- Country
- CRMD United States
- LENZ United States
- Employees
- CRMD N/A
- LENZ N/A
- Industry
- CRMD Biotechnology: Pharmaceutical Preparations
- LENZ Medicinal Chemicals and Botanical Products
- Sector
- CRMD Health Care
- LENZ Health Care
- Exchange
- CRMD Nasdaq
- LENZ Nasdaq
- Market Cap
- CRMD 645.0M
- LENZ 679.4M
- IPO Year
- CRMD 2010
- LENZ 2021
- Fundamental
- Price
- CRMD $10.13
- LENZ $23.49
- Analyst Decision
- CRMD Strong Buy
- LENZ Strong Buy
- Analyst Count
- CRMD 6
- LENZ 6
- Target Price
- CRMD $15.67
- LENZ $35.40
- AVG Volume (30 Days)
- CRMD 906.0K
- LENZ 100.2K
- Earning Date
- CRMD 03-11-2025
- LENZ 11-06-2024
- Dividend Yield
- CRMD N/A
- LENZ 61.39%
- EPS Growth
- CRMD N/A
- LENZ N/A
- EPS
- CRMD N/A
- LENZ N/A
- Revenue
- CRMD $12,262,234.00
- LENZ N/A
- Revenue This Year
- CRMD N/A
- LENZ N/A
- Revenue Next Year
- CRMD $234.92
- LENZ N/A
- P/E Ratio
- CRMD N/A
- LENZ N/A
- Revenue Growth
- CRMD 41184.20
- LENZ N/A
- 52 Week Low
- CRMD $3.03
- LENZ $2.57
- 52 Week High
- CRMD $13.85
- LENZ $38.93
- Technical
- Relative Strength Index (RSI)
- CRMD 44.90
- LENZ 35.48
- Support Level
- CRMD $9.79
- LENZ $24.01
- Resistance Level
- CRMD $11.28
- LENZ $25.90
- Average True Range (ATR)
- CRMD 0.51
- LENZ 1.08
- MACD
- CRMD -0.05
- LENZ 0.02
- Stochastic Oscillator
- CRMD 23.84
- LENZ 9.02
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.
About LENZ LENZ Therapeutics Inc. Common Stock
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.